MacuShield Reviews


Harry Marsland - Retired Optician

"Great Improvement In Sight After Taking MacuShield"

As a retired optician, Harry Marsland knew better than most how serious it was when he was diagnosed with an untreatable eye condition.

But his tale of despair has turned into an astonishing story of recovery – thanks to the marigold plant.

Mr Marsland, who at one stage needed help just to walk, could be the first person in the UK to have recovered from a devastating condition that causes blindness.

Harry Marsland from Oundle, Northants (UK), has found a  way to improve his own eye sight

Within months of starting to take a food supplement containing marigold extracts he is driving a car again, reads without a magnifier and has near-perfect vision in the affected eye.

Mr Marsland, 73, suffered from age related macular degeneration (AMD), which is responsible for half the cases of blindness in the country.

After a number of standard vitamin treatments, which can only slow decline anyway, failed to work, he was handed a flyer that had been gathering dust in a doctor’s drawer for almost a year.

It promoted a vitamin supplement called Macushield, which contains mesozeaxanthin, derived from marigolds.

‘I now know, professionally that I have recovered almost completely from the effects in my left eye,’ he said yesterday. ‘I am the first person to have such good fortune.’

Mr Marsland, from Oundle, Northamptonshire, started taking a 2mg capsule daily in April 2007. He paid £150 for it as it is not available on the NHS.

He has been blind in one eye since gambling on an experimental laser treatment in 2001, but the vision in his other eye is now 95 per cent as good as it was before.

‘It was in August my wife Nina picked up my magnifying glass and realised it was dusty,’ he said. ‘She was the first to realise I no longer needed to use it.

‘A few months later we were walking in the dark and I suddenly realised I was no longer holding on to my wife. It’s miraculous, considering at one point I was literally blind in the dark.’ Dry age-related macular degeneration happens when light-sensitive cells slowly break down.


Norah Norton

Norah Norton

"Could not read road signs at night before taking MacuShield"

GRADUALLY LOSING her eyesight to age-related macular degeneration (AMD), the prognosis for Norah Norton in 2006 was not good. Her job as an editor of catalogues for art exhibitions commissioned by Cork County Council was becoming increasingly difficult. Proof-reading hard copy was impossible. She could read only very big fonts on her computer and had to be helped by her daughter to proof any paperwork.

“About four years ago, I began to notice that straight lines seemed to be jagged,” says 65-year-old Norton. “Everything on TV was distorted and my night vision totally went to pot. I had to stop driving at night because oncoming headlights seemed to bleed into each other. I couldn’t read big signs on the road at night.”

An eye specialist who treated her son for a problem prior to 2006 had also examined Norton’s eyes and told her that she was likely to suffer from AMD as she got older. The condition was diagnosed by Norton’s ophthalmologist four years ago.

“He said that the norm would be for it to progress and suggested that I start thinking about moving from my home in the countryside to Cork city as driving, both during the night and the day, would become an issue.”

AMD is the leading cause of irreversible blindness in people over 50 years of age, affecting an estimated 70,000 people in Ireland. This disease results in a loss of central vision preventing sufferers from reading, watching TV, recognising faces or driving.

It’s believed that damage by free radicals within the eye cause AMD. Free radicals are unstable molecules and are produced in response to oxygen and to blue light entering the eyes. Because we breath oxygen and are constantly exposed to blue light, damage caused by free radicals is unavoidable.

The main risk factors for AMD are increasing age, cigarette smoking and a family history of the condition. The treatment for AMD includes expensive injections in the eye that suit only some patients.

Norton’s life was transformed when, three years ago, she heard an item on the radio about a supplement called MacuShield. She learned that it was being trial tested at Waterford Institute of Technology (WIT) and that it “stopped or delayed deterioration”.

Norton immediately ordered it over the counter, from her local pharmacist and takes a daily capsule. “After about six months taking the supplement, I could see out the back door at night again. People on television weren’t distorted anymore. The white lines in the middle of the road were straight again. Bit by bit, my eyesight started to improve. My driving is fine. I just wear glasses for driving and watching movies as I’m short sighted.”

MacuShield contains the three key ingredients that make up macular pigment at the back of the eye. The deterioration in this pigment – made up of lutein, zeaxanthin and meso-zeaxanthin – has long been suspected to be a major factor in the onset of AMD.

Dr John Nolan, an expert on AMD and director of the Macular Pigment Research Group at WIT, has been testing MacuShield in clinical trials. “We have seen very beneficial results and very promising anecdotal cases where patients have reported improvement in their eye sight. We’re committed to continuing investigations.

“For me, MacuShield is a preventative supplement as opposed to a magical cure. The reason it stops the disease from developing is because it is an antioxidant that filters light. It’s like a protective sun cream for the eye.”

Can it reverse AMD? “We don’t know. We don’t want to give patients out there false hope until we know more, but MacuShield is promising.”

The medical community “is kind of split” in its response to MacuShield. “There are people who are in favour of nutritional supplementation. But a lot of the medical community simply doesn’t look at the full body of evidence that is available. There’s very little in it for them as they’re trained to treat and not to prevent.”

Dr Nolan is currently collaborating with the University of Wisconsin in a study whereby AMD patients are being put on one of three supplements, including MacuShield, to see which has the best result.

“With our growing ageing population, AMD, already an epidemic, is going to double in the next 10 years. We have to be pro-active about preventative strategies.”


Contact us with your latest success story with Macushield.